Clinical Trials in Austria

• Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan… Pending
  2025-522167-15-00 Phase III Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC) Genmab A/S
• A Study to Investigate Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis (KATALYST-AV) Pending
  2025-522176-86-01 Phase III Moderate Calcific Aortic Valve Stenosis (CAVS) Kardigan Inc.
• A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending
  2025-522373-10-00 Phase III Progressive pulmonary fibrosis and Idiopathic pulmonary fibr… Bristol-Myers Squibb Services Unlimited Company
• LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 Pending
  2025-522475-28-00 Phase III Pulmonary Hypertension (PH) with Heart Failure with preserve… Tenax Therapeutics Inc.
• A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L… Pending
  2025-522818-23-00 Phase III Small Cell Lung Cancer (SCLC) Zai Lab (US) LLC
• An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending
  2025-522983-33-00 Phase III Chronic rhinosinusitis with nasal polyps Sanofi-Aventis Recherche & Developpement
• Cangrelor safety and pharmacodynamics in paediatric subjects with congenital heart disease Pending
  2025-523109-14-00 Phase III Congenital Heart Disease Chiesi Farmaceutici S.p.A.
• IJAMP-Trial Pending
  2025-523131-19-00 Phase IV prick test-induced itch Johannes Kepler University Linz
• Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) Pending
  2025-523389-26-00 Phase III Relapsed/refractory primary central nervous system lymphoma Deciphera Pharmaceuticals Inc.
• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t… Pending
  2025-523555-66-00 Phase III Myelofibrosis Novartis Pharma AG
• Efgartigimod as a first line attack therapy in demyelinating diseases of the central nervous system Pending
  2025-523654-13-00 Phase II/III Demyelinating diseases Medizinische Hochschule Hannover
• A clinical study to investigate the safety and tolerability of efimosfermin alfa injection in participants with known or suspected F2- or F3… Pending
  2025-523674-16-00 Phase III Metabolic Dysfunction-Associated Steatohepatitis (MASH) Glaxosmithkline Research & Development Limited
• A pivotal clinical study to investigate the safety and efficacy of efimosfermin alfa injection in participants with biopsyconfirmed F2- or F… Pending
  2025-523675-39-00 Phase III Metabolic Dysfunction-Associated Steatohepatitis (MASH) Glaxosmithkline Research & Development Limited
• The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – … Pending
  2025-523676-23-00 Phase IV ST-elevation acute coronary syndrome Medical University Of Vienna
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat… Pending
  2025-523735-19-00 Phase III Metastatic Microsatellite Stable Colorectal Cancer Incyte Corp.
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 Phase II Homeostatic iron regulator gene-related hereditary hemochrom… CSL Behring LLC
• A pivotal study of N-Acetyl-L-Leucine on CACNA1A Disorders Pending
  2025-523828-51-00 Phase III CACNA1A Disorders IntraBio Inc; Intrabio Limited
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta… Pending
  2025-523869-22-00 Phase III advanced or metastatic extrapulmonary neuroendocrine carcino… Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
• Efanesoctocog alfa treatment in patients with congenital hemophilia A suffering from inflammation of joint lining Pending
  2025-523896-44-00 Phase III Congenital hemophilia A (HA) GWT-Tud GmbH
• First study evaluating the safety and dosage of YG-01 in patients with a malignant brain tumor Pending
  2025-524299-44-00 Phase I Glioblastoma Ygion Biomedical GmbH
• A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending
  2025-524322-18-00 Phase III Non-active Secondary Progressive Multiple Sclerosis (SPMS) Zenas Biopharma (USA) LLC
• DIRECTION Study Pending
  2025-524495-39-00 Phase IV Chronic Rhinosinusitis with Nasal Polyps Medical University Of Vienna
• Pharmacokinetics of Aztreonam-Avibactam in Critically Ill Patients with Sepsis Receiving ECMO Support: A Prospective PK Study Pending
  2025-524614-28-00 Phase I (Other) Sepsis Medical University Of Vienna
• Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combination for Inflammatory Bowel Disease Pending
  2025-524640-35-00 Phase II Ulcerative colitis (Inflammatory Bowel Disease) Spyre Therapeutics Inc.

Showing 49–72 of 1,115 trials